Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $0.66 in the prior trading day, BioAtla Inc (NASDAQ: BCAB) closed at $0.67, up 1.37%. In other words, the price has increased by $1.37 from its previous closing price. On the day, 0.52 million shares were traded. BCAB stock price reached its highest trading level at $0.6779 during the session, while it also had its lowest trading level at $0.6131.
Ratios:
Our goal is to gain a better understanding of BCAB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.24.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.JMP Securities initiated its Mkt Outperform rating on September 15, 2022, with a $17 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 39548988 and an Enterprise Value of 27386990. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.59. Its current Enterprise Value per Revenue stands at 2.49 whereas that against EBITDA is -0.438.
Stock Price History:
The Beta on a monthly basis for BCAB is 1.03, which has changed by -0.6776699 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, BCAB has reached a high of $2.53, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -0.97%, while the 200-Day Moving Average is calculated to be 44.58%.
Shares Statistics:
The stock has traded on average 990.97K shares per day over the past 3-months and 903110 shares per day over the last 10 days, according to various share statistics. A total of 58.72M shares are outstanding, with a floating share count of 45.42M. Insiders hold about 22.65% of the company’s shares, while institutions hold 15.39% stake in the company. Shares short for BCAB as of 1760486400 were 3000731 with a Short Ratio of 3.03, compared to 1757894400 on 4306197. Therefore, it implies a Short% of Shares Outstanding of 3000731 and a Short% of Float of 5.7299999999999995.
Earnings Estimates
. The current rating of BioAtla Inc (BCAB) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.22 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$1.06 and -$1.3 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.2, with 3.0 analysts recommending between -$0.71 and -$1.59.
